<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744339</url>
  </required_header>
  <id_info>
    <org_study_id>RIO-40400</org_study_id>
    <secondary_id>2014-003055-60</secondary_id>
    <nct_id>NCT02744339</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>DYNAMIC</acronym>
  <official_title>Evaluation of the Pharmacodynamic Effects of Riociguat in Subjects With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction in a Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to&#xD;
&#xD;
      â€¢ Assess the pharmacodynamic profile of riociguat in subjects with symptomatic pulmonary&#xD;
      hypertension and heart failure with preserved ejection fraction&#xD;
&#xD;
      The secondary objectives of this study are to&#xD;
&#xD;
        -  Assess safety and tolerability of riociguat in this study population&#xD;
&#xD;
        -  Assess changes in dimensions of left and right ventricles and cardiac function&#xD;
           parameters using cardiac magnetic resonance imaging&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of cardiac output at rest, measured by right heart catheterization</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline of cardiac output at rest, measured by right heart catheterization after 26 weeks of study drug treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac magnetic resonance imaging parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in right ventricular ejection fraction by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac magnetic resonance imaging parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in right ventricular volume by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac magnetic resonance imaging parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in left atrial area by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac magnetic resonance imaging parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in right atrial area by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemodynamic parameters other than cardiac output</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in pulmonary vascular resistance by right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemodynamic parameters other than cardiac output</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in pulmonary arterial wedge pressure by right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemodynamic parameters other than cardiac output</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in transpulmonary gradient by right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemodynamic parameters other than cardiac output</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in systemic vascular resistance by right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in WHO functional class</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biomarker levels</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in serum N-terminal prohormone B-type natriuretic peptide (NTproBNP)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in T1-mapping parameters by CMR</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in native T1 times of the left ventricular myocardium</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in T1-mapping parameters by CMR</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in extracellular volume of the left ventricular myocardium</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in left ventricular end-systolic volume by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in left ventricular end-diastolic volume by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in tricuspid annular plan systolic excursion by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in pressure gradient of tricuspid valve by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in diameter of inferior vena cava by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in respiratory collapsibility of inferior vena cava by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in mitral peak velocity of early (E) filling by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in mitral peak velocity of late (A) filling by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in E-wave deceleration time by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in left ventricular ejection fraction by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in estimate of mean right atrial pressure by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in systolic pulmonary artery pressure by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in echocardiography parameters</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Change from baseline in E/A ratio by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in exercise capacity: 6-minute walk distance</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in exercise capacity: Borg CR 10 scale</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in quality of life scores: EQ-5D</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in quality of life scores: MLHF</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Events of special interest</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Events of special interest considered for calculation of the combined endpoint &quot;time to clinical worsening&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Composite endpoint</measure>
    <time_frame>Baseline and 26 weeks after study drug treatment</time_frame>
    <description>Composite endpoint as defined by: time to death from cardiovascular causes or first hospitalization for a cardiovascular event, including acute or worsening heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Riociguat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riociguat up-titrated to a maximum of 1.5mg TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo sham-titrated TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat</intervention_name>
    <description>Adempas up-titrated to max. 1.5mg TID</description>
    <arm_group_label>Riociguat</arm_group_label>
    <other_name>Adempas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sham-titrated TID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to &lt;80 years of age at the time of informed consent (The lower age limit may be&#xD;
             higher if legally required in participating countries.)&#xD;
&#xD;
          -  Male and female subjects with symptomatic PH and HF-PEF (group 2 / 2.2 of Dana Point&#xD;
             classification(4) and WHO class II to IV) (Other groups of PH, especially HF-REF, PAH,&#xD;
             CTEPH, must have been ruled out according to accepted diagnostic procedures and&#xD;
             guidelines, see section 5.1.2 Exclusion criteria.)&#xD;
&#xD;
          -  PH-HF-PEF defined as:&#xD;
&#xD;
               -  LVEF â‰¥50%, diagnosed by echocardiography or left heart catheterization (LHC)&#xD;
                  within 30 days before randomization&#xD;
&#xD;
               -  PAPmean â‰¥25 mmHg at rest, measured by RHC&#xD;
&#xD;
               -  PAWP &gt;15 mmHg at rest, measured by RHC&#xD;
&#xD;
          -  Optimized therapy for hypertension&#xD;
&#xD;
          -  The dose regimen of the background treatment must have been stable for &gt;30 days before&#xD;
             randomization. Diuretic therapy must have been stable for â‰¥1 week.&#xD;
&#xD;
          -  RHC results for the definite diagnosis of PH not older than 12 weeks at Visit 1. RHC&#xD;
             must have been performed in the participating center under standardized conditions&#xD;
&#xD;
          -  CMRI must be performed at Visit 1 (baseline) or must not be older than 12 weeks with&#xD;
             all parameters measured as listed in Section 7.3.3&#xD;
&#xD;
          -  Women are eligible if not of childbearing potential, defined as:&#xD;
&#xD;
          -  Postmenopausal women (i.e. last menstrual bleeding at least 2 years before&#xD;
             randomization)&#xD;
&#xD;
          -  Women with bilateral tubal ligation&#xD;
&#xD;
          -  Women with bilateral ovariectomy&#xD;
&#xD;
          -  Women with hysterectomy or, if of childbearing potential, women are eligible if&#xD;
&#xD;
          -  A serum pregnancy test is negative at the pre-study visit, and The woman uses a&#xD;
             combination of condoms and a safe and highly effective contraception method (hormonal&#xD;
             contraception with implants or combined oral contraceptives, certain intrauterine&#xD;
             devices) for the entire duration of the study.&#xD;
&#xD;
          -  Able to understand and follow instructions and to participate in the study for its&#xD;
             entire duration&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PH in groups other than group 2.2 according to Dana Point classification.(4) In&#xD;
             particular, PAH, CTEPH, and HF-REF must have been ruled out according to accepted&#xD;
             diagnostic procedures and guidelines.&#xD;
&#xD;
          -  Cardiac decompensation, with hospitalization or visit to the emergency department,&#xD;
&#xD;
             â‰¤30 days before randomization&#xD;
&#xD;
          -  Left heart disease because of to ischemic heart disease or dilated cardiomyopathy&#xD;
&#xD;
          -  Resynchronization therapy at any time&#xD;
&#xD;
          -  Need for intravenous (IV) diuretics â‰¤30 days before randomization&#xD;
&#xD;
          -  Treatment with inotropes or IV vasodilators â‰¤30 days before randomization&#xD;
&#xD;
          -  Pre-treatment with endothelin receptor antagonists (ERAs), phosphodiesterase type 5&#xD;
             (PDE5) inhibitors, or prostanoids â‰¤30 days before randomization, or with nitrates â‰¤7&#xD;
             days before randomization&#xD;
&#xD;
          -  Subjects who medically require treatment with drugs that are not in line with the in-&#xD;
             or exclusion criteria of this study or that are prohibited concomitant medications&#xD;
             (see section 6.9) for this study&#xD;
&#xD;
          -  Bronchial asthma or chronic obstructive pulmonary disease (COPD) with forced&#xD;
             expiratory volume in 1 second (FEV1) &lt;60% of predicted&#xD;
&#xD;
          -  Restrictive lung disease with total lung capacity (TLC) &lt;60% of predicted&#xD;
&#xD;
          -  Subjects on oxygen therapy&#xD;
&#xD;
          -  Severe congenital abnormalities of the lung, thorax, or diaphragm&#xD;
&#xD;
          -  Clinically relevant hepatic dysfunction shown by:&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) â‰¥3 times the upper limit of normal (ULN) or&#xD;
&#xD;
          -  Child Pugh stage B and C in cirrhotic subjects&#xD;
&#xD;
          -  Severe renal impairment (glomerular filtration rate [GFR] &lt;30mL/min/1.73 m2 calculated&#xD;
             by the Modification of Diet in Renal Disease [MDRD] formula)&#xD;
&#xD;
          -  Uncontrolled arterial hypertension (SBP &gt;180 mmHg or diastolic blood pressure [DBP]&#xD;
             &gt;110 mmHg)&#xD;
&#xD;
          -  SBP &lt;110 mmHg at baseline&#xD;
&#xD;
          -  Myocardial disease, such as ischemic or dilative infiltrative myocardial disease (i.e.&#xD;
             amyloidosis, hypertrophic cardiomyopathy)&#xD;
&#xD;
          -  Severe aortic or mitral stenosis, or any such stenosis with indication for surgery&#xD;
&#xD;
          -  Coronary artery disease with angina of Canadian Cardiovascular Society (CCS) class III&#xD;
             or IV or requiring nitrates, unstable angina, or acute myocardial infarction &lt;90 days&#xD;
             before randomization&#xD;
&#xD;
          -  Reperfusion procedure (percutaneous coronary intervention [PCI] or coronary artery&#xD;
             bypass graft [CABG]) &lt;90 days before randomization, or &lt;21 days in case of a negative&#xD;
             stress test effect after PCI&#xD;
&#xD;
          -  Stroke with persistent neurological deficit&#xD;
&#xD;
          -  Subjects positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Resting HR while awake of &lt;50 beats per minute (BPM) or &gt;105 BPM (in case of atrial&#xD;
             fibrillation &gt;110 BPM)&#xD;
&#xD;
          -  Participation in another clinical study &lt;90 days before randomization&#xD;
&#xD;
          -  Subjects with a medical disorder, condition, or history thereof that in the opinion of&#xD;
             the investigator would impair the subject's ability to participate or complete the&#xD;
             26-week study&#xD;
&#xD;
          -  Subjects with underlying medical disorders with an anticipated life expectancy below 2&#xD;
             years because of a non-cardiac disease (e.g. active cancer disease with localized and&#xD;
             / or metastasized tumor mass)&#xD;
&#xD;
          -  Subjects with a history of multiple drug allergies&#xD;
&#xD;
          -  Subjects with hypersensitivity to the investigational drug or any of the excipients&#xD;
&#xD;
          -  Previous assignment to treatment during this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Bonderman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Kastner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>DBonderman</investigator_full_name>
    <investigator_title>Assoc.Prof.Priv.Doz.Dr.</investigator_title>
  </responsible_party>
  <keyword>PH-HFpEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riociguat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

